Project title: Measurement of gelsolin levels
NIAID Principal Investigator: John Gallin, M.D.
Chief, Clinical Pathophysiology Section (LCIM)
NIH Associate Director for Clinical Research
Chief Scientific Officer of the NIH Clinical Center
Does plasma gelsolin correlate to clinical outcome of COVID-19?
Plasma gelsolin is thought be an important anti-inflammatory protein. Low levels have been associated with poor prognosis in pneumonia in the intensive care unit setting and as an important biomarker of chronic granulomatous disease, especially in patients with active pneumonia. Thus, the Clinical Pathophysiology Section of the Laboratory of Clinical Immunology and Microbiology (LCIM) plans to evaluate gelsolin levels in COVID-19-infected patients using an enzyme-linked immunosorbent assay (ELISA). Low levels correlating with mortality could be an important biomarker for disease and may suggest a potential therapeutic role for exogenously administered gelsolin.
5 µL of serum or plasma is required. Ideally, samples would be taken 1) upon hospital admission, 2) during hospitalization, 3) at discharge, and 4) after discharge.